Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics).
News innovation
Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care
Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect from...
more ...Single Mouse Trials: mimicking clinical phase II trials in PDX models with manageable costs and efforts
The long and successful collaboration of EPO Berlin-Buch GmbH with the Charité University Hospital in Berlin recently led to the following publication
more ...Calling all young STEM talent
The 57th edition of the “Jugend forscht” competition will soon kick off under the theme “Lass Zukunft da.” The MDC is once again co-sponsoring the search for tomorrow’s scientists – this year to be he...
more ...Events Campus
14.09.2021, 09:00
GMP Biotech Summer School
Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)
more ...
